Cypherpunk Technologies has acquired an additional 56,418.09 ZEC for approximately $29 million at an average price of $514.02 per ZEC. This latest acquisition follows a series of strategic purchases over the preceding months. With this transaction, Cypherpunk's total Zcash holdings now stand at 290,062.67 ZEC, representing an estimated 1.76% of the total circulating network supply. The company's total ZEC position was acquired at a cumulative average price of $334.41 per ZEC. "We continue to execute on our goal of accumulating 5% of the Zcash network." said Will McEvoy, CIO of Cypherpunk. "As our Zcash position grows, we are well positioned for a market that is repricing the societal importance of privacy. We are excited to continue executing on our Zcash strategy while expanding our work across a broader set of privacy-preserving technologies and initiatives."
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
